EcoDrugPlus

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSPLAG00000016110
Gene Symbol: GABRG3
4 Cross references
215 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSPLAG00000014399
Gene Symbol: GABBR1
3 Cross references
196 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 2

Ensembl ID : ENSPLAG00000002866
Gene Symbol: GABBR2
3 Cross references
208 Possible Orthologues:

Gamma-Secretase Subunit Aph-1b

Ensembl ID : ENSPLAG00000021201
Gene Symbol: LOC106935386
3 Cross references
190 Possible Orthologues:

Glucagon Like Peptide 2 Receptor

Ensembl ID : ENSPLAG00000013878
Gene Symbol: GLP2R
4 Cross references
205 Possible Orthologues:

Glucagon Receptor-Like

Ensembl ID : ENSPLAG00000018850
Gene Symbol: LOC106947547
2 Cross references
203 Possible Orthologues:

Glucocorticoid Receptor-Like

Ensembl ID : ENSPLAG00000020243
Gene Symbol: LOC106955406
3 Cross references
161 Possible Orthologues:

Glucokinase

Ensembl ID : ENSPLAG00000012267
Gene Symbol: GCK
3 Cross references
211 Possible Orthologues:

Glucosylceramidase Beta 1

Ensembl ID : ENSPLAG00000018987
Gene Symbol: GBA1
3 Cross references
251 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 2

Ensembl ID : ENSPLAG00000004841
Gene Symbol: GRIA2
3 Cross references
242 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 2

Ensembl ID : ENSPLAG00000010808
Gene Symbol: GRIA2
4 Cross references
204 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 1

Ensembl ID : ENSPLAG00000011931
Gene Symbol: GRIN1
3 Cross references
205 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).